Study Overview
Let's Talk About It
![](/img/heroes/hero_boxing-ring-2_mobile.jpg)
![](/img/heroes/hero_boxing-ring-2.jpg)
![](/img/warriors/story_dominique_mobile.jpg)
![](/img/warriors/story_dominique.jpg)
The Time is Now
Mitapivat is a potential new therapy for the pain crises and anemia of sickle cell disease. There have been two studies for mitapivat so far — a smaller phase 1 study and a phase 2 study. Now the next part of RISE UP, a phase 3 study, is enrolling Warriors.
PHASE 3 (Now Enrolling)
![Phase 3 screening period up to 28 days, 52-week double-blind period, primary endpoints, 216-week open-label extension period, and safety follow-up around 4 weeks after last dose](/img/dtp-phase3-desktop.png)
![Phase 3 screening period up to 28 days, 52-week double-blind period, primary endpoints, 216-week open-label extension period, and safety follow-up around 4 weeks after last dose](/img/dtp-phase3-mobile.png)